How I treat relapsed and/or refractory multiple myeloma
The expanding therapeutic landscape of relapsed and/or refractory multiple myeloma (RRMM) has contributed to significant improvements in patient outcomes. These have included combinations of proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), monoclonal antibodies (mAbs), histone deacetylas...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
MDPI AG
2020-09-01
|
| Colección: | Hematology Reports |
| Materias: | |
| Acceso en línea: | https://www.pagepress.org/journals/index.php/hr/article/view/8955 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|